COMMUNIQUÉS West-GlobeNewswire

-
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
30/06/2025 -
Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement
30/06/2025 -
CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025
30/06/2025 -
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
30/06/2025 -
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period
30/06/2025 -
Synergy CHC Corp. (NASDAQ: SNYR) Secures Landmark Retail and Distribution Wins Across North America for FOCUSfactor Supplements and Functional Beverages
30/06/2025 -
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
30/06/2025 -
SPR Receives Fourth Consecutive Northeast Ohio Top Workplaces Award
30/06/2025 -
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
30/06/2025 -
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
30/06/2025 -
HealthLynked Appoints Andrew Mavliev as Chief Technology and Product Officer to Accelerate Direct-to-Consumer Healthcare Innovation
30/06/2025 -
Tilde Sciences Announces Availability Of VECAMYL™ (Mecamylamine) With Exclusive Distribution Through Optime Care Specialty Pharmacy
30/06/2025 -
Tectonic Therapeutic Joins Russell 3000® Index
30/06/2025 -
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
30/06/2025 -
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
30/06/2025 -
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
30/06/2025 -
Protara Therapeutics Announces Addition to the Russell 3000® Index
30/06/2025 -
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
30/06/2025 -
Spectral AI Announces Submission to FDA of its DeepView® System
30/06/2025
Pages